Sign In

Login

Password

Forgot Password ? Sign Up

Insulin degludec (Vietnamese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Insulin degludec" in Vietnamese language version.

refsWebsite
Global rank Vietnamese rank
8nih.gov
4th place
7th place
5doi.org
2nd place
2nd place
3web.archive.org
1st place
1st place
2europa.eu
68th place
114th place
1novonordisk.com
low place
low place
1reuters.com
49th place
78th place
1fda.gov
447th place
625th place
1novonordisk-us.com
low place
low place

doi.org

  • Klein, O; Lynge, J; Endahl, L; Damholt, B; Nosek, L; Heise, T (2007). “Albumin-bound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetes”. Diabetes, Obesity and Metabolism. 9 (3): 290–9. doi:10.1111/j.1463-1326.2006.00685.x. PMID 17391154.
  • Haahr, H; Heise, T (2014). “A review of the pharmacological properties of insulin degludec and their clinical relevance”. Clinical Pharmacokinetics. 53 (9): 787–800. doi:10.1007/s40262-014-0165-y. PMC 4156782. PMID 25179915.
  • Wang, F; Surh, J; Kaur, M (2012). “Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review”. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 5: 191–204. doi:10.2147/DMSO.S21979. PMC 3402007. PMID 22826637.
  • Nasrallah, SN; Reynolds, LR (2012). “Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?”. Clinical Medicine Insights. Endocrinology and Diabetes. 5: 31–7. doi:10.4137/CMED.S9494. PMC 3411522. PMID 22879797.
  • Robinson, JD; Neumiller, JJ; Campbell, RK (ngày 2 tháng 11 năm 2012). “Can a New Ultra-Long-Acting Insulin Analogue Improve Patient Care? Investigating the Potential Role of Insulin Degludec”. Drugs. 72 (18): 2319–25. doi:10.2165/11642240-000000000-00000. PMID 23145524.

europa.eu

ema.europa.eu

ec.europa.eu

fda.gov

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Klein, O; Lynge, J; Endahl, L; Damholt, B; Nosek, L; Heise, T (2007). “Albumin-bound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetes”. Diabetes, Obesity and Metabolism. 9 (3): 290–9. doi:10.1111/j.1463-1326.2006.00685.x. PMID 17391154.
  • Haahr, H; Heise, T (2014). “A review of the pharmacological properties of insulin degludec and their clinical relevance”. Clinical Pharmacokinetics. 53 (9): 787–800. doi:10.1007/s40262-014-0165-y. PMC 4156782. PMID 25179915.
  • Wang, F; Surh, J; Kaur, M (2012). “Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review”. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 5: 191–204. doi:10.2147/DMSO.S21979. PMC 3402007. PMID 22826637.
  • Nasrallah, SN; Reynolds, LR (2012). “Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?”. Clinical Medicine Insights. Endocrinology and Diabetes. 5: 31–7. doi:10.4137/CMED.S9494. PMC 3411522. PMID 22879797.
  • Robinson, JD; Neumiller, JJ; Campbell, RK (ngày 2 tháng 11 năm 2012). “Can a New Ultra-Long-Acting Insulin Analogue Improve Patient Care? Investigating the Potential Role of Insulin Degludec”. Drugs. 72 (18): 2319–25. doi:10.2165/11642240-000000000-00000. PMID 23145524.

ncbi.nlm.nih.gov

novonordisk-us.com

press.novonordisk-us.com

novonordisk.com

reuters.com

web.archive.org